A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma

This study tests a combination of CAR-T cell therapy (a high-tech treatment where your own immune cells are engineered to fight cancer) with targeted radiation for people with follicular lymphoma that has come back or stopped responding to treatment. **You may be eligible if...** - You are 18 or older - You have been diagnosed with follicular lymphoma (grades 1–3A) confirmed by biopsy - Your lymphoma has relapsed or did not respond to at least 2 prior treatments - You are in good enough health to tolerate CAR-T therapy (your kidneys, liver, and blood counts meet certain thresholds) - You have at least one measurable tumor on imaging **You may NOT be eligible if...** - You have another active cancer requiring treatment in the past 3 years (skin cancers excluded) - You are pregnant or breastfeeding - You have an uncontrolled serious infection - You have a severe allergy to aminoglycoside antibiotics Talk to your doctor to see if this trial is right for you.